Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LTC4S | Q16873 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2755475 | 0.91 | LTC4S (0.49) | NR4A2MAOBMRGPRX4MAPK14P4HTM | |
| SCHEMBL239586 | 0.87 | P4HTM (0.49) | MAOBMRGPRX4FFAR1FFAR4P4HTM | |
| SCHEMBL239377 | 0.86 | RXRA (0.54) | NR4A2MAOBMRGPRX4P4HTMLTC4S | |
| SCHEMBL2755476 | 0.84 | MAOB (0.48) | MAOBMRGPRX4FFAR1FFAR4P4HTM | |
| SCHEMBL238898 | 0.83 | SCN9A (0.49) | LTC4SSCN9A | |
| SCHEMBL236056 | 0.83 | PTGDR2 (0.47) | MAOBMRGPRX4P4HTMMAPTLTC4S | |
| SCHEMBL238805 | 0.80 | LTC4S (0.63) | LTC4S | |
| SCHEMBL2755473 | 0.80 | RXRA (0.51) | NR4A2MAOBMRGPRX4LTC4S | |
| SCHEMBL241183 | 0.80 | LTC4S (0.51) | LTC4SSCN9A | |
| SCHEMBL239379 | 0.78 | LTC4S (0.73) | LTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | NR4A2 1253/4885MAOB 96/4885MRGPRX4 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.